Piper Sandler analyst Joseph Catanzaro raised the firm’s price target on Catalyst Pharmaceuticals to $18 from $16 and keeps an Overweight rating on the shares. Catalyst reported Q3 Firdapse revenues of $57.2M, well ahead of consensus, and increased Firdapse revenue to $205M-$210M, Catanzaro tells investors in a research note. Firdapse continues to grow, driven by a low discontinuation rate and organic growth, including increased enrollment of tumor-LEMS patients, the analyst says.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CPRX:
- Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
- Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
- Catalyst Pharmaceuticals announces FDA approval of sNDA for FIRDAPSE
- Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients
- CPRX, BMY: Insiders are Selling These 2 Pharma Stocks; Should You?